The neuroprotective effect of memantine during cardiopulmonary bypass
Phase 1
- Conditions
- Ischemic heart diseases.Chronic ischemic heart disease
- Registration Number
- IRCT20200502047276N1
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Patients that are candidate for open heart surgery
Age between 18 to 80 years
Exclusion Criteria
Acute or chronic renal failure (AKI stage 4 or 5)
Creatinine clearance less than 30 ml/min
Moderate to severe hepatic failure
Autoimmune disease
Alzheimer or dementia
History of memantine consumption within last 6 months
History of seizure, CVA, or psychiatric disorders
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method S100B protein level during preoperative and postoperative courses. Timepoint: before surgery, after cardiopulmonary bypass weaning, 6 hours after surgery, 24 hours after surgery. Method of measurement: Enzyme linked immunoassay (ELISA), Human Protein S100-B(S100B)ELISA Kit.
- Secondary Outcome Measures
Name Time Method eurological deficits. Timepoint: Post-operation up to 30 days. Method of measurement: Neurological examination.